# Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

> **NCT06495125** · PHASE2 · RECRUITING · sponsor: **Emory University** · enrollment: 50 (estimated)

## Conditions studied

- Advanced Lung Adenocarcinoma
- Refractory Lung Adenocarcinoma
- Stage III Lung Cancer AJCC v8
- Stage IV Lung Cancer AJCC v8

## Interventions

- **DRUG:** Avutometinib
- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **DRUG:** Defactinib
- **BIOLOGICAL:** Nivolumab
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT06495125
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-31
- **Primary completion:** 2029-03-17
- **Final completion:** 2029-09-17
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06495125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06495125, "Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06495125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*